help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LAVIOLETTE, M.
Right arrow Articles by REISS, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LAVIOLETTE, M.
Right arrow Articles by REISS, T. F.

Am. J. Respir. Crit. Care Med., Volume 160, Number 6, December 1999, 1862-1868

Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma

MICHEL LAVIOLETTE, KERSTIN MALMSTROM, SUSAN LU, PAUL CHERVINSKY, JEAN-CLAUDE PUJET, IZABELLA PESZEK, JI ZHANG, and THEODORE F. REISS, for the Montelukast/Beclomethasone Additivity Group

Bronchology Unit, Centre de Recherche de l'Hôpital Laval, Sainte-Foy, Québec, Canada; Department of Pulmonary/Immunology, Statistics Program and Department of Biostatistics, Merck Research Laboratories, Rahway, New Jersey; New England Research Center, Inc., North Dartmouth, Massachusetts; and Centre de Diagnostic et de Réadaptation Respiratoire, Paris, France

The primary objective of this study was to determine whether montelukast, an oral leukotriene receptor antagonist, provides additional clinical benefit to the effect of inhaled corticosteroids. A total of 642 patients with chronic asthma (FEV1 50 to 85% of predicted value and at least a predefined level of asthma symptoms) incompletely controlled with inhaled beclomethasone, 200 µg twice daily using a spacer device, during the 4-wk run-in period were randomly allocated, in a double-blind, double-dummy manner to one of four treatment groups: (1) montelukast 10 mg plus continuing inhaled beclomethasone; (2) placebo tablet plus continuing inhaled beclomethasone; (3) montelukast 10 mg and inhaled placebo (after blind beclomethasone removal); and (4) placebo tablet and inhaled placebo (after blind beclomethasone removal). The primary endpoints were FEV1 and daytime asthma symptoms score. Montelukast provided significant (p < 0.05) clinical benefit in addition to inhaled beclomethasone by improving FEV1, daytime asthma symptom scores, and nocturnal awakenings. Blind removal of beclomethasone in the presence of placebo tablets caused worsening of asthma control, demonstrating that patients received clinical benefit from inhaled corticosteroids. Blind removal of beclomethasone in the presence of montelukast resulted in less asthma control but not to the level of the placebo group. All treatments were well tolerated; clinical and laboratory adverse experiences were generally similar to placebo treatment in this study. In conclusion, montelukast provided additional asthma control to patients benefitting from, but incompletely controlled on, inhaled beclomethasone. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet J-C, Peszek I, Zhang J, Reiss TF for the Montelukast/Beclomethasone Additivity Group. Montelukast added to inhaled beclomethasone in treatment of asthma.




This article has been cited by other articles:


Home page
 ThoraxHome page
S Joos, A Miksch, J Szecsenyi, B Wieseler, U Grouven, T Kaiser, and A Schneider
Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review
Thorax, May 1, 2008; 63(5): 453 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al.
Global strategy for asthma management and prevention: GINA executive summary
Eur. Respir. J., January 1, 2008; 31(1): 143 - 178.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Peters-Golden and W. R. Henderson Jr.
Leukotrienes
N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854.
[Full Text] [PDF]

Home page
 ThoraxHome page
J. Travers, S. Marsh, M. Williams, M. Weatherall, B. Caldwell, P. Shirtcliffe, S. Aldington, and R. Beasley
External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?
Thorax, March 1, 2007; 62(3): 219 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Barnes
Spoilt for Choice?
Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 208 - 209.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
The American Lung Association Asthma Clinical Rese
Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma
Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 235 - 242.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Kraft, C. B. Cairns, M. C. Ellison, J. Pak, C. Irvin, and S. Wenzel
Improvements in Distal Lung Function Correlate With Asthma Symptoms After Treatment With Oral Montelukast
Chest, December 1, 2006; 130(6): 1726 - 1732.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Humbert
The Right Tools at the Right Time
Chest, July 1, 2006; 130(1_suppl): 29S - 40S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. H. Green, C. E. Brightling, S. McKenna, B. Hargadon, N. Neale, D. Parker, C. Ruse, I. P. Hall, and I. D. Pavord
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Eur. Respir. J., June 1, 2006; 27(6): 1144 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. A. Biernacki, S. A. Kharitonov, H. M. Biernacka, and P. J. Barnes
Effect of Montelukast on Exhaled Leukotrienes and Quality of Life in Asthmatic Patients
Chest, October 1, 2005; 128(4): 1958 - 1963.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. P. Currie, D. K. C. Lee, and P. Srivastava
Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?
Chest, October 1, 2005; 128(4): 2954 - 2962.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. Busse and M. Kraft
Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy
Chest, April 1, 2005; 127(4): 1312 - 1326.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
G.P. Currie, P. Srivastava, O.J. Dempsey, and D.K.C. Lee
Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists
QJM, March 1, 2005; 98(3): 171 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. Jayaram, M. Duong, M. M. M. Pizzichini, E. Pizzichini, D. Kamada, A. Efthimiadis, and F. E. Hargreave
Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma
Eur. Respir. J., January 1, 2005; 25(1): 41 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
G. Riccioni, R. D. Vecchia, M. Castronuovo, C. Di Ilio, and N. D'Orazio
Tapering Dose of Inhaled Budesonide in Subjects with Mild-to-Moderate Persistent Asthma Treated with Montelukast: A 16-Week Single-Blind Randomized Study
Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 285 - 289.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. D. Sin, J. Man, H. Sharpe, W. Q. Gan, and S. F. P. Man
Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis
JAMA, July 21, 2004; 292(3): 367 - 376.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. L. Bahna
Is It Time to Reduce Our Phobia of Inhaled Corticosteroids?
Pediatrics, June 1, 2004; 113(6): 1813 - 1814.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. S. Mendes, M. A. Campos, A. Hurtado, and A. Wanner
Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma
Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1131 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D.-W. Perng, H.-Y. Huang, Y.-C. Lee, and R.-P. Perng
Leukotriene Modifier vs Inhaled Corticosteroid in Mild-to-Moderate Asthma: Clinical and Anti-inflammatory Effects
Chest, May 1, 2004; 125(5): 1693 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. Snyder, P. D. Blanc, P. P. Katz, E. H. Yelin, and M. D. Eisner
Leukotriene Modifier Use and Asthma Severity: How Is a New Medication Being Used by Adults With Asthma?
Arch Intern Med, March 22, 2004; 164(6): 617 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. S. Jalba, G. J. Rodrigo, C. Rodrigo, C. A. Camargo Jr., M.-P. Malice, S. A. Green, and T. F. Reiss
Intravenous Montelukast in Acute Asthma
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 130 - 131.
[Full Text]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
Y. Cai, L. Bjermer, and T. S. Halstensen
Bronchial Mast Cells Are the Dominating LTC4S-Expressing Cells in Aspirin-Tolerant Asthma
Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 683 - 693.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
L. Bjermer, H. Bisgaard, J. Bousquet, L. M Fabbri, A. P Greening, T. Haahtela, S. T Holgate, C. Picado, J. Menten, S B. Dass, et al.
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial
BMJ, October 18, 2003; 327(7420): 891.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. P. Currie, D. K. C. Lee, K. Haggart, C. E. Bates, and B. J. Lipworth
Effects of Montelukast on Surrogate Inflammatory Markers in Corticosteroid-treated Patients with Asthma
Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1232 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
F. M Ducharme
Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence
BMJ, March 22, 2003; 326(7390): 621 - 621.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
N C Thomson and M Shepherd
Leukotriene receptor antagonists as add-on therapy for adults with asthma
Thorax, March 1, 2003; 58(3): 190 - 192.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M J Vaquerizo, P Casan, J Castillo, M Perpina, J Sanchis, V Sobradillo, A Valencia, H Verea, J L Viejo, C Villasante, et al.
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
Thorax, March 1, 2003; 58(3): 204 - 210.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D B Price, D Hernandez, P Magyar, J Fiterman, K M Beeh, I G James, S Konstantopoulos, R Rojas, J A van Noord, M Pons, et al.
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
Thorax, March 1, 2003; 58(3): 211 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. O'Sullivan, M. Akveld, C. M. Burke, and L. W. Poulter
Effect of the Addition of Montelukast to Inhaled Fluticasone Propionate on Airway Inflammation
Am. J. Respir. Crit. Care Med., March 1, 2003; 167(5): 745 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
W. M. Abraham
Of Mice and Men
Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 1 - 4.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
F. Kanniess, K. Richter, S. Bohme, R.A. Jorres, and H. Magnussen
Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma
Eur. Respir. J., October 1, 2002; 20(4): 853 - 858.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
F. G. Miller and A. F. Shorr
Unnecessary Use of Placebo Controls: The Case of Asthma Clinical Trials
Arch Intern Med, August 12, 2002; 162(15): 1673 - 1677.
[Full Text] [PDF]

Home page
 ChestHome page
O. J. Dempsey, S. J. Fowler, A. Wilson, G. Kennedy, and B. J. Lipworth
Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma*
Chest, July 1, 2002; 122(1): 151 - 159.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
F. M Ducharme
Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence
BMJ, June 29, 2002; 324(7353): 1545 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
L. J Mazur
Montelukast moderately decreased asthma symptoms in children with persistent asthma
Evid. Based Med., May 1, 2002; 7(3): 77 - 77.
[Full Text] [PDF]

Home page
 ChestHome page
F. G. Miller and A. F. Shorr
Ethical Assessment of Industry-Sponsored Clinical Trials* : A Case Analysis
Chest, April 1, 2002; 121(4): 1337 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. J. Lipworth and C. M. Jackson
Bronchodilator Reversibility to Albuterol Predicts Bronchodilator Response to Salmeterol
Chest, April 1, 2002; 121(4): 1382 - 1382.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
P.J. Barnes
Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids
Eur. Respir. J., January 1, 2002; 19(1): 182 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S.-E. DAHLEN, K. MALMSTROM, E. NIZANKOWSKA, B. DAHLEN, P. KUNA, M. KOWALSKI, W. R. LUMRY, C. PICADO, D. D. STEVENSON, J. BOUSQUET, et al.
Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial
Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 9 - 14.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. R. Botkin, E. Clayton, R. Nelson, B. Wilfond, M. A. Munger, F. G. Miller, A. F. Shorr, L. Friedman Ross, S. J. Fowler, B. J. Lipworth, et al.
Salmeterol and Inhaled Corticosteroids in Patients With Persistent Asthma
JAMA, December 26, 2001; 286(24): 3075 - 3078.
[Full Text] [PDF]

Home page
 BMJHome page
H. A M Kerstjens, H. J Groen, and W. van der Bij
Recent advances: Respiratory medicine
BMJ, December 8, 2001; 323(7325): 1349 - 1353.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
N. Roche, T. Lepage, J. Bourcereau, and P. Terrioux
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Eur. Respir. J., December 1, 2001; 18(6): 903 - 908.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]

Home page
 PediatricsHome page
B. Knorr, L. M. Franchi, H. Bisgaard, J. H. Vermeulen, P. LeSouef, N. Santanello, T. M. Michele, T. F. Reiss, H. H. Nguyen, and D. L. Bratton
Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
Pediatrics, September 1, 2001; 108(3): e48 - 48.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. N. BLACK, F. BLASI, C. R. JENKINS, R. SCICCHITANO, G. D. MILLS, A. R. RUBINFELD, R. E. RUFFIN, P. R. MULLINS, J. DANGAIN, B. C. COOPER, et al.
Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection with Chlamydia pneumoniae
Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 536 - 541.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. E. Fish, E. Israel, J. J. Murray, A. Emmett, R. Boone, S. W. Yancey, and K. A. Rickard
Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy
Chest, August 1, 2001; 120(2): 423 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. V. Bourdet and D. Williams
Management Considerations for Chronic Asthma
Journal of Pharmacy Practice, April 1, 2001; 14(2): 108 - 125.
[Abstract] [PDF]

Home page
 PediatricsHome page
H. Bisgaard
Leukotriene Modifiers in Pediatric Asthma Management
Pediatrics, February 1, 2001; 107(2): 381 - 390.
[Abstract] [Full Text]

Home page
 Postgrad. Med. J.Home page
O J Dempsey
Leukotriene receptor antagonist therapy
Postgrad. Med. J., December 1, 2000; 76(902): 767 - 773.
[Abstract] [Full Text]

Home page
 JAMAHome page
W. W. Busse
A 47-Year-Old Woman With Severe Asthma
JAMA, November 1, 2000; 284(17): 2225 - 2233.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
G. Ménard and E. Y. Bissonnette
Priming of Alveolar Macrophages by Leukotriene D4 . Potentiation of Inflammation
Am. J. Respir. Cell Mol. Biol., October 1, 2000; 23(4): 572 - 577.
[Abstract] [Full Text]

Home page
 Arch Intern MedHome page
A. Reicin, R. White, S. F. Weinstein, A. F. Finn Jr, H. Nguyen, I. Peszek, L. Geissler, B. C. Seidenberg, and for the Montelukast/Loratadine Study Group
Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma
Arch Intern Med, September 11, 2000; 160(16): 2481 - 2488.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. A. Stempel, M. LAVIOLETTE, K. MALMSTROM, and T. F. REISS
MONTELUKAST ADDED TO INHALED BECLOMETHASONE IN TREATMENT OF ASTHMA
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 331 - 332.
[Full Text]

Home page
 JWatch GeneralHome page
Are Inhaled Steroids and Leukotriene Antagonists Additive for Asthma?
Journal Watch (General), January 7, 2000; 2000(107): 5 - 5.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society